MA-to-MA switching among dually eligible beneficiaries rose sharply from 2016 to 2022, AJMC study author Grace Mackleby, PhD, found.

Sustainable models require asking what a result shows, what design produced it, and whether the design was built to measure value or just produce a number.

Panelists say drug price negotiation, Medicaid changes, prior authorization, and 340B reform strain community oncology.

The 2026 COA Payer Exchange and Innovation Summit began with a panel on AI and the ever-changing digital infrastructure in community oncology.

Although PMOS Awareness Month has ended, the conversation continues, with experts saying closing diagnostic and care gaps requires ongoing efforts.

Among people with HIV, lung cancer screening eligibility rose from 6% to 15% in 6 years, but uptake stayed under 30%.

CMS finalized the mandatory GLOBE Model, tying Part B drug rebates to international prices in areas covering 25% of beneficiaries from Jan. 1, 2027.

Average stand-alone Part D premiums are projected to rise by less than $1 a month as a temporary subsidy program ends after 2026.